Improved drug efficacy assessment using joint Bayesian estimation framework
Project Number5R01EB035093-02
Contact PI/Project LeaderMARIN, THIBAULT
Awardee OrganizationYALE UNIVERSITY
Description
Abstract Text
Abstract
The development of central nervous system (CNS) drugs requires imaging tools that can
quantify drug efficacy and target engagement as well as the effects of drug concentration on
these quantitative assessment measures. Positron emission tomography (PET) imaging has
become standard practice for quantitative assessment, thanks to its ability to image tracers that
bind to target receptors of drugs. Receptor occupancy (RO) studies, which consist in a pair of
PET scans, baseline and post-drug injection, can be used to quantify, as a function of drug
concentration, the blocking effect of a drug. The concentration yielding half-maximum blocking
effect, called EC50, is determined by first estimating receptor occupancy for each pair of scans,
then fitting a logistic model to the occupancy vs. concentration curve. The conventional method
to estimate RO and EC50 consists in reconstructing the dynamic PET data for each pair of
scans, perform kinetic fitting, typically in high binding regions, to estimate the binding potential
and calculate RO, before performing the logistic fit across concentrations to obtain EC50. The
resulting estimates have low precision due to the noise in dynamic PET images and the lack of
proper noise modeling. Moreover, estimating single RO and EC50 values discards potentially
valuable information on the spatial distribution of RO and EC50. We propose an estimation
framework that jointly estimates spatial RO maps for each pair of scans and a global EC50 map
using an end-to-end model from the PET measurements to the estimated EC50. The estimation
framework relies on advanced optimization strategies to decompose the joint estimation process
into manageable subproblems, such as image reconstruction, parametric fitting, image
denoising and logistic fitting. The method is expected to improve the estimation of RO and EC50
over conventional methods, while offering additional spatial information. The targeted
improvement in estimation would allow to reduce the sample size required in drug trials to
achieve the same statistical power as conventional approaches (or conversely, increase the
statistical power for a fixed sample size). The method will be validated in numerical simulations
and applied to in vivo animal studies.
Public Health Relevance Statement
Narrative
We propose a novel joint parametric reconstruction framework to improve the estimation of drug
receptor occupancy and half-maximum blocking effect from PET receptor occupancy studies.
The goal is to reduce the sample size required to characterize central nervous system drugs
and therefore facilitate drug development.
National Institute of Biomedical Imaging and Bioengineering
CFDA Code
286
DUNS Number
043207562
UEI
FL6GV84CKN57
Project Start Date
17-May-2024
Project End Date
29-February-2028
Budget Start Date
01-March-2025
Budget End Date
28-February-2026
Project Funding Information for 2025
Total Funding
$387,830
Direct Costs
$231,540
Indirect Costs
$156,290
Year
Funding IC
FY Total Cost by IC
2025
National Institute of Biomedical Imaging and Bioengineering
$387,830
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R01EB035093-02
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R01EB035093-02
Patents
No Patents information available for 5R01EB035093-02
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R01EB035093-02
Clinical Studies
No Clinical Studies information available for 5R01EB035093-02
News and More
Related News Releases
No news release information available for 5R01EB035093-02
History
No Historical information available for 5R01EB035093-02
Similar Projects
No Similar Projects information available for 5R01EB035093-02